Navigation Links
Chindex International, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results
Date:2/8/2010

BETHESDA, Md., Feb. 8 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the third quarter and first nine months of fiscal year 2010.

    Financial Highlights:
    -- Revenue in the third quarter of fiscal year 2010 increased 12% year
       over year to $46.5 million;
    -- Net income for the third quarter of fiscal 2010 increased to $3.9
       million, or $0.24 per diluted share, from $846,000, or $0.05 per
       diluted share in the prior year period;
    -- The Company received a refund of $3.3 million for business tax paid
       since January 1, 2009 in the Healthcare Services division, equivalent
       to approximately $0.15 per diluted share;
    -- Revenue in the first nine months of 2009 increased 16.2% year over year
       to $129.9 million;
    -- Net income for the first nine months of 2009 increased to $7.7 million,
       or $0.48 per diluted share, from $1.5 million, or $0.10 per diluted
       share in the prior year period.

Roberta Lipson, President and CEO of Chindex, commented, "We are pleased with our profitability and year to date performance which reflect substantial improvements over last year. In the Healthcare Services division we are in a development cycle with operations in the Beijing market experiencing capacity limitations as we build out the expansion facilities. At the same time, operations in the Shanghai and Guangzhou markets continue along expected growth trajectories. The Medical Products division is always subject to quarterly fluctuations, and although we are seeing significant improvements over last year, we are experiencing regulatory delays on high-value medical equipment purchases. Nevertheless, there continues to be significant excitement in the marketplace for our products, particularly for the daVinci surgical robot and the new S/SC 2000 ultrasound platform. As we enter the fourth quarter, and look forward into our next fiscal year, we remain extremely well-positioned to capitalize on China's premium-quality healthcare services market, continued economic vibrancy and opportunities created by healthcare reform."

Revenue in the third quarter of fiscal year 2010 increased 12% to $46.5 million from $41.6 million in the third quarter of fiscal year 2009. Revenue from the Healthcare Services division increased 5% to $21.6 million from $20.5 million in the third quarter of fiscal year 2009, and reflected growing inpatient and outpatient volume offset by disruption due to construction of the expanded facility in Beijing. The Company expects the negative impact of the expansion work to continue through the opening of the expanded facilities, currently planned for the fall of 2010. Revenue from the Medical Products division increased 18% to $24.9 million from $21.1 million in the prior year period, reflecting the increase in sales of women's health imaging products and the delivery of two robotic surgical systems. During this quarter, the Company also recorded revenues of approximately $3.2 million under its current KfW Development Bank contracts.

During the quarter, the Company recorded income from operations of $6.6 million, compared to income from operations of $1.9 million in the same quarter last year. Income from operations includes the benefit of a $3.3 million business tax refund related to the Healthcare Services division. This tax refund is equivalent to approximately $0.15 per diluted share. Total operating costs and expenses for the third quarter of fiscal year 2010 were flat on a year over year basis and included $269,000 of development and startup expenses for new clinics, equivalent to $0.02 per diluted share, and non-cash stock compensation expense of $888,000, or $0.05 per diluted share. In the prior period, the Company's development and startup expense were $662,000, or $0.04 per diluted share, and non-cash stock compensation expense was $810,000, or $0.05 per diluted share.

The Company recorded a $2.7 million provision for taxes, or an effective tax rate of 41.1%, in the third quarter of fiscal year 2010 as compared to a provision for taxes of $658,000, or an effective tax rate of 43.7%, in the prior year period. The tax rate reflects losses in entities for which the Company cannot yet recognize a benefit.

Net income for the quarter ended December 31, 2009 was $3.9 million, or $0.24 per diluted share. Excluding the tax refund explained above, net income for the third quarter of fiscal year 2010 would be $1,497,000, or $0.09 per diluted share. This compares to net income of $846,000, or $0.05 per diluted share, in the prior year period.

Healthcare Services division business results:

For the third quarter of fiscal year 2010, revenue increased 5% to $21.6 million from $20.5 million for the prior year quarter. The increase reflected growing inpatient and outpatient volume offset by disruption due to construction of the expanded facility in Beijing.

Excluding the $3.3 million tax benefit discussed above, operating costs increased by 5% to $19.3 million, and income from operations before foreign exchange gains increased to $5.6 million from $2.1 million in the prior year period.

Lipson continued, "We were pleased to see our revenue increase sequentially and on a year over year basis despite the temporary disruption at our BJU facility, which should more than double our capacity by calendar year-end. We were also particularly excited to receive a $3.3 million business tax rebate and receive a business tax exemption going forward. We believe this treatment from authorities in the for-profit hospital sector, is evidence that healthcare reform efforts in China will continue to drive growth throughout the sector and further enhance our position as the leading, private sector provider in the premium-care market."

Medical Products division business results:

For the third quarter of fiscal year 2010, revenue increased 18% to $24.9 million from $21.1 million in the prior year quarter. Revenue performance mainly reflected increases in sales of women's health imaging products and delivery of two robotic surgical systems.

Revenue performance year to date also reflects continued delays in the order cycle for high value capital medical equipment, particularly for robotic surgical systems, resulting from the Chinese government's review of these technologies as well as the overall timing of the tender process in China. Sales excluding daVinci were lower than the prior year period, reflecting the introduction of a new generation of technology in diagnostic ultrasound which replaced the previous market leading product. During this quarter, the Company also recorded revenues of approximately $3.2 million under its current KfW Development Bank contracts.

Gross profit for the Medical Products division increased to $7.3 million from $5.6 million in the prior year's third quarter, representing an increase in gross profit margin to 29% from 26% in the year over year period. The variance in gross profit margin is in line with historical averages.

Lipson concluded, "The government's review of high value technologies used in public hospitals is a routine process impacting new, big ticket medical products. We believe that the review itself substantiates the continued demand we see for premium medical technology in China, and bodes well for future sales across our portfolio despite causing disruptions to daVinci sales this quarter."

Fiscal 2010 Third Quarter Conference Call

Management will host a conference call today at 8:00 am ET to discuss financial results.

To participate in the conference call, international callers should dial 1-719-325-4757 and domestic callers should dial 1-877-874-1568 approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available on the day of the call at (international) 1-719-457-0820 and (domestic) 1-888-203-1112 and continue to be available through February 22, 2010.

This call is also being webcast and will be accessible at Chindex's website http://ir.chindex.com/events.cfm . The event will be archived and available for replay through February 22, 2010.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and http://www.unitedfamilyhospitals.com .

Safe Harbor Statement

Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in our annual report on Form 10-K for the year ended March 31, 2009, updates and additions to those "Risk Factors" in our interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have no obligation to update these forward-looking statements.


                          Financial Summary Attached



                         CHINDEX INTERNATIONAL, INC.
               CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
                (in thousands except share and per share data)
                                 (Unaudited)

                                Three months ended       Nine months ended
                                   December 31,             December 31,
                                 2009        2008        2009         2008

    Product sales              $24,921     $21,070     $65,324      $52,607
    Healthcare services
     revenue                    21,563      20,530      64,610       59,171
    Total revenue               46,484      41,600     129,934      111,778

    Cost and expenses
     Product sales costs        17,652      15,493      47,506       38,576
     Healthcare services
      costs                     14,699      17,185      48,801       49,586
     Selling and marketing
      expenses                   3,841       3,867      10,609        9,590
     General and
      administrative
      expenses                   3,699       3,158       9,740        9,728
     Income from operations      6,593       1,897      13,278        4,298
     Other (expenses) and
      income
     Interest expense             (230)       (259)       (784)        (738)
     Interest income               477         527       1,350        1,316
     Miscellaneous
     (expense) income -
     net                          (220)       (661)       (851)      (1,257)
    Income before income
     taxes                       6,620       1,504      12,993        3,619
    Provision for income
     taxes                      (2,722)       (658)     (5,304)      (2,073)
    Net income                  $3,898        $846      $7,689       $1,546
    Net income per common
     share - basic                $.27        $.06        $.53         $.11
    Weighted average shares
     outstanding - basic    14,592,992  14,455,237  14,533,601   14,395,239
    Net income per common
     share - diluted              $.24        $.05        $.48         $.10
    Weighted average
     shares outstanding
     - diluted              16,211,607  15,836,521  16,127,180   16,089,705



                         CHINDEX INTERNATIONAL, INC.
                    CONSOLIDATED CONDENSED BALANCE SHEETS
                       (in thousands except share data)
                                 (Unaudited)
                                                    December 31,    March 31,
                                                        2009          2009

                        ASSETS
    Current assets:
    Cash and cash equivalents                          $23,760       $20,293
    Restricted cash                                        450         1,854
    Investments                                         57,672        51,502
       Accounts receivable, less allowance for
        doubtful accounts of $5,661 and $5,041,
        respectively
                 Product sales receivables              30,608        37,994
                 Patient service receivables             9,699         8,837
    Inventories, net                                    13,444        11,346
    Deferred income taxes                                3,255         2,410
    Other current assets                                 3,329         3,239
    Total current assets                               142,217       137,475
    Restricted cash                                      2,402         1,437
    Investments                                            322            --
    Property and equipment, net                         21,386        20,633
    Noncurrent deferred income taxes                        29         1,031
    Other assets                                         2,923         2,061
       Total assets                                   $169,279      $162,637

         LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Short-term debt, current portion of long-term
     debt and vendor financing                          $2,613        $1,631
    Current portion of capitalized leases                   --            22
    Accounts payable                                    10,366        12,259
    Accrued expenses                                    14,577        20,607
    Other current liabilities                            6,660         4,148
    Deferred revenue                                     2,394         1,539
    Income taxes payable                                 2,939         1,568
    Total current liabilities                           39,549        41,774
    Long-term debt, vendor financing and
     convertible debentures                             21,578        23,709
    Long-term deferred revenue                           1,151           595
    Long-term deferred tax liability                       119           119
    Total liabilities                                   62,397        66,197
    Commitments and contingencies
    Stockholders' equity:
       Preferred stock, $.01 par value, 500,000
        shares authorized, none issued                      --            --
       Common stock, $.01 par value, 28,200,000
        shares authorized, including
         3,200,000 designated Class B:
       Common stock - 13,717,768 and
         13,452,007 shares issued and
         outstanding at December 31, 2009
         and March 31, 2009, respectively                  137           135
       Class B stock - 1,162,500 shares issued
         and outstanding at December 31,
         2009 and March 31, 2009, respectively              12            12
       Additional paid-in capital                       98,728        95,808
       Accumulated other comprehensive income            3,044         3,072
       Retained earnings (accumulated deficit)           4,961        (2,587)
                Total stockholders' equity             106,882        96,440
                    Total liabilities and
                     stockholders' equity             $169,279      $162,637



                         CHINDEX INTERNATIONAL, INC.
                             SEGMENT INFORMATION

The Company operates in two businesses: Healthcare Services and Medical Products. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes, not including foreign exchange gains or losses. The following segment information has been provided per Statement of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information:" (in thousands except percentages)


                                        Healthcare     Medical
                                         Services     Products     Total
    For the three months ended
     December 31, 2009:
    Sales and service revenue             $21,563      $24,921    $46,484
    Gross Profit                            n/a *        7,269        n/a
    Gross Profit %                          n/a *          29%        n/a
    Income from operations before
     foreign exchange                      $5,637       $1,265     $6,902
    Foreign exchange loss                                            (309)
    Income from operations                                         $6,593
    Other income, net                                                  27
    Income before income taxes                                     $6,620
    Assets as of December 31, 2009       $106,242      $63,037   $169,279


                                       Healthcare      Medical
                                        Services      Products     Total
    For the three months ended
     December 31, 2008:
    Sales and service revenue             $20,530      $21,070    $41,600
    Gross Profit                            n/a *        5,577        n/a
    Gross Profit %                          n/a *          26%        n/a
    Income (loss) from operations
     before foreign exchange               $2,142        $(630)    $1,512
    Foreign exchange gain                                             385
    Income from operations                                         $1,897
    Other (expense), net                                             (393)
    Income before income taxes                                     $1,504
    Assets as of March 31, 2009           $94,675      $67,962   $162,637


                                        Healthcare     Medical
                                         Services     Products     Total
    For the nine months ended
     December 31, 2009:
    Sales and service revenue             $64,610      $65,324   $129,934
    Gross Profit                            n/a *       17,818        n/a
    Gross Profit %                          n/a *          27%        n/a
    Income from operations before
     foreign exchange                     $12,043          $25    $12,068
    Foreign exchange gain                                           1,210
    Income from operations                                        $13,278
    Other (expense), net                                             (285)
    Income before income taxes                                    $12,993
    Assets as of December 31, 2009       $106,242      $63,037   $169,279


                                        Healthcare     Medical
                                         Services     Products     Total
    For the nine months ended
     December 31, 2008:
    Sales and service revenue             $59,171      $52,607   $111,778
    Gross Profit                            n/a *       14,031        n/a
    Gross Profit %                          n/a *          27%        n/a
    Income (loss) from operations
     before foreign exchange               $5,970      $(2,185)    $3,785
    Foreign exchange gain                                             513
    Income from operations                                         $4,298
    Other (expense), net                                             (679)
    Income before income taxes                                     $3,619
    Assets as of March 31, 2009           $94,675      $67,962   $162,637

    * Gross profit margins are not routinely calculated in the healthcare
      service industry.


    For more information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel:   +1-646-277-1227

SOURCE Chindex International, Inc.

RELATED LINKS
http://www.chindex.com
http://www.unitedfamilyhospitals.com
http://ir.chindex.com/events.cfm

'/>"/>

SOURCE Chindex International, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine news :

1. Chindex International Announces September Investor Conferences Participation
2. Chindex International, Inc. Announces New CDC Contract
3. Chindex International, Inc. Reports First Quarter Fiscal 2010 Financial Results
4. Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products
5. Chindex International, Inc. Launches World-Class Cancer Treatment Center
6. Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results
7. Chindex International and Vital Images Sign Reseller Agreement
8. Chindex International, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
9. Chindex International, Inc. Announces May Conference Participation
10. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
11. Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... grout cleaning and sealing company , is proud to announce that many of ... superior levels of customer service. The hard surface restoration franchises received customer recognition ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... Prize has officially been won. A team from 21st Century Medicine (21CM) ( ... way to preserve the delicate neural circuits of an intact rabbit brain for ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag ... into the Food & Beverage and Dietary Supplement market ... throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... Texas (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous for ... members and significant others that they are loved. This year, for more than 5.6 ... they cost - just won't be enough to remind them of the lives they’ve led ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 8, 2016  Echo Therapeutics, Inc. (Nasdaq: ... focused on non-invasive continuous glucose monitoring (CGM) ... that it will host a webcast and ... at 9:00 a.m. Eastern Time to provide ... strategy, advancements in its CGM system, and ...
(Date:2/8/2016)... In a historic vote among its members this weekend, the Shinnecock Indian ... facility and dispensary on tribal land near Southampton . ... provider for patients in the state,s Medical Cannabis Program. --> ... patients in the state,s Medical Cannabis Program. --> Tribal ... pursue designation from the State of New York ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. , ... biological and chemical manufacturing, and Kodiak Sciences Inc., a ... treatment of retinal disease, announced today agreements for the ... Lonza will manufacture material at multiple sites, including Slough ... --> --> Retinal diseases, such ...
Breaking Medicine Technology: